Novel chikungunya and dengue vaccines-travel medicine applications

Robert Steffen; Davidson H Hamer; Lin H Chen; Eric Caumes; Colleen L Lau

doi:10.1093/jtm/taae064

Novel chikungunya and dengue vaccines-travel medicine applications

J Travel Med. 2024 Apr 18:taae064. doi: 10.1093/jtm/taae064. Online ahead of print.

Authors

Robert Steffen^{1

2}, Davidson H Hamer³, Lin H Chen^{4

5}, Eric Caumes⁶, Colleen L Lau⁷

Affiliations

¹ Epidemiology, Biostatistics and Prevention Institute, Department of Public and Global Health, Division of Infectious Diseases, World Health Organization Collaborating Centre for Travelers' Health, University of Zurich, Switzerland.
² Division of Epidemiology, Human Genetics & Environmental Sciences, University of Texas School of Public Health, Houston, TX, U.S.A.
³ Department of Global Health, Boston University School of Public Health; Section of Infectious Diseases, Department of Medicine, Boston University Chobanian & Avedisian School of Medicine; and Center on Emerging Infectious Disease, Boston University, Boston, MA, USA.
⁴ Division of Infectious Diseases and Travel Medicine, Mount Auburn Hospital, Cambridge, MA, USA.
⁵ Faculty of Medicine, Harvard Medical School, Boston, MA, USA.
⁶ Infectious and Tropical Diseases. Hopital de l'Hotel-Dieu & Sorbonne University, Paris, France.
⁷ UQ Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Herston, Australia.

PMID: 38637307
DOI: 10.1093/jtm/taae064

Abstract

Recent epidemics of dengue and chikungunya have highlighted the urgent need for vaccines to reduce the risk of infection in travellers. Given challenges tracking chikungunya outbreaks in real-time and the widespread resurgence of dengue, broader indications for the use of the new chikungunya and dengue vaccines should be considered.

Keywords: Antibody dependent enhancement; Arbovirus; Ixchiq; Mosquito-borne; Prevention; Qdenga.